IBA (Ion Beam Applications)

IBA (Ion Beam Applications S.A.), is a medical technology company which concentrates its activities on the fight against cancer through integrated and innovative solutions for the diagnosis and treatment of the disease. The Group focuses on the development of equipment for radiopharmaceuticals production centers and the development of proton therapy (PT), the most advanced form of radiotherapy today.
Website
Proton therapy is increasingly considered the most advanced and targeted cancer treatment due to its superior dose distribution and fewer side effects. Protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor and sparing healthy surrounding tissue.
IBA RadioPharma Solutions helps nuclear medicine departments in hospitals and radiopharmaceutical distribution centers to design, build, equip and operate a radiopharmacy. IBA equipment includes the multi-purpose automated synthesizer Synthera® for the production of 18F-FDG, other 18F-labeled compounds (18FCH, 18FLT, Na18F) and future radiopharmaceuticals.
IBA PT systems account for more 50% of the world's clinically based PT facilities. While, end of 2012, proton therapy represents less than 1% of radiotherapy treatments, studies estimate that more than 17% by radiotherapy would benefit from being treated by this technique.
IBA RadioPharma Solutions' growth perspectives are positive with the increased demand for Positron Emission Tomography (PET) radiopharmaceuticals throughout the world, particularly in emerging countries. In addition, Synthera® is designed to accomodate a wide range of radiochemistries and R&D development.
IBA is involved in several collaboration projects with universities, poles of activity and business partners. While IBA Proton therapy has been involved in two MecaTech and two BioWin projects, IBA RadioPharma Solutions has been involved in one BioWin project.
Project scopes are highly diversified: conceptual research like methodologies for treating moving tumors; technological development like a compact isocentric gantry structure; on metrology and quality assurance such as dosimetry and treatment planning; or software development for patient scheduling.
Micheline Desmedt

E-mail: info@iba-group.com 
Phone: +32 10 475 811 
Fax: +32 10 475 810

Chemin du Cyclotron 3
1348 Louvain-la-Neuve